D3 dopamine receptor, behavioral sensitization, and psychosis

Neuroscience and Biobehavioral Reviews

Volumn 25, Issue 5, 2001, Pages 427-443

  Richtand, Neil M ^a,b   Woods, Stephen C ^b   Berger, S Paul ^a,b   Strakowski, Stephen M ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Amphetamine; Behavioral sensitization; Cocaine; Dopamine D3 receptor; Psychosis; Schizophrenia; Stimulant drugs

Indexed keywords

2 DIPROPYLAMINO 5 METHOXY 1 METHYLTETRALIN; 2 DIPROPYLAMINO 5,6 DIMETHOXYINDAN; 2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; 5 METHOXY 1 METHYL 2 PROPYLAMINOTETRALIN; AMPHETAMINE; COCAINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; NAFADOTRIDE;

BEHAVIOR; BINDING COMPETITION; BRAIN REGION; DOPAMINE RECEPTOR BLOCKING; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; LOCOMOTION; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOSIS; RECEPTOR AFFINITY; RECEPTOR DOWN REGULATION; RECEPTOR OCCUPANCY; REVIEW; SENSITIZATION; SEROTONINERGIC SYSTEM; STIMULATION;

EID: 0034837911     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(01)00023-9     Document Type: Article

References (200)

1. Long-term administration of d-amphetamine: Progressive augmentation of motor activity and stereotypy
2. The experimental reproduction of amphetamine psychosis
3. Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis
4. Neurochemical sensitization in the pathophysiology of schizophrenia: Deficits and dysfunction in neuronal regulation and plasticity
5. Multiple daily amphetamine administration: Behavioral and neurochemical alterations
6. Time course of transient behavioral depression and persistent behavioral sensitization in relation to regional brain monoamine concentrations during amphetamine withdrawal in rats
7. Amphetamine psychosis: I. Description of the individuals and process
8. Dextroamphetamine: Evaluation of psychotomimetic properties in man
9. Factors that predict individual vulnerability to amphetamine self-administration
10. The neural basis of drug craving: An incentive-sensitization theory of addiction
11. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder
12. Criteria for rationally evaluating animal models of posttraumatic stress disorder
13. Behavioral and neurochemical characteristics of stimulant-induced augmentation
14. Psychomotor stimulant-induced sensitization: Behavioral and neurochemical correlates
15. Effects of lesions of prefrontal cortex, amygdala, or fornix on behavioral sensitization to amphetamine: Comparison with N-methyl-D-aspartate antagonists
16. Two dissociable components of behavioral sensitization following repeated amphetamine administration
17. Animal models of stimulant-induced psychosis
18. Disintegration into stereotypy induced by drugs or brain damage: A microdescriptive behavioural analysis
19. Evolving behavior in the clinical and experimental amphetamine (model) psychosis
20. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity
21. The role of the nucleus accumbens in sensitization to drugs of abuse
22. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants
23. Effects of repeated amphetamine treatment on the locomotor activity of the dopamine D1A-deficient mouse
24. Behavioral responses to cocaine and amphetamine administration in mice lacking the dopamine D1 receptor
25. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants
26. Environmental and pharmacological sensitization: Effects of repeated administration of systemic or intra-nucleus accumbens cocaine
27. Infusion of a D-1 receptor agonist into the nucleus accumbens enhances cocaine-induced behavioural sensitization
28. Alterations in amphetamine-induced locomotor activity and stereotypy after electrical stimulation of the nucleus accumbens and neostriatum
29. Behavioral sensitization is accompanied by an enhancement in amphetamine-stimulated dopamine release from striatal tissue in vitro
30. Subchronic methamphetamine treatment enhances methamphetamine- or cocaine-induced dopamine efflux in vivo
31. Persistent sensitization of dopamine neurotransmission in ventral striatum (nucleus accumbens) produced by prior experience with (+)-amphetamine: A microdialysis study in freely moving rats
32. Time course of the development of the enhanced behavioral and biochemical responses to amphetamine after pretreatment with amphetamine
33. Differential development of autoreceptor subsensitivity and enhanced dopamine release during amphetamine sensitization
34. In vivo microdialysis reveals a diminished amphetamine-induced DA response corresponding to behavioral sensitization produced by repeated amphetamine pretreatment
35. Reduction of dopamine release and synthesis by repeated amphetamine treatment: Role in behavioral sensitization
36. Blockade of behavioral sensitization to cocaine and amphetamine by inhibitors of protein synthesis
37. Application of a protein synthesis inhibitor into the ventral tegmental area, but not the nucleus accumbens, prevents behavioral sensitization to cocaine
38. Evidence for the involvement of phospholipase A2 mechanisms in the development of stimulant sensitization
39. Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system
40. Dopamine receptors: From structure to function
41. Cloning and expression of a rat D2 dopamine receptor cDNA
42. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics
43. The D3 dopamine receptor: Neurobiology and potential clinical relevance
44. The putative dopamine D3 receptor agonist 7-OH-DPAT: Lack of mesolimbic selectivity
45. Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice
46. Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin
47. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: Comparison with dopamine D2 receptor mRNA
48. Regional quantification of D1, D2, and D3 dopamine receptor mRNA in rat brain using a ribonuclease protection assay
49. Differential visualization of dopamine D2 and D3 receptor sites in rat brain. A comparative study using in situ hybridization histochemistry and ligand binding autoradiography
50. Distribution of dopamine D3 receptor expressing neurons in the human forebrain: Comparison with D2 receptor expressing neurons
51. Differential distribution of D3 dopamine receptors in the brains of several mammalian species
52. Dopamine D3 receptors expressed by all mesencephalic dopamine neurons
53. The third dopamine receptor (D3) as a novel target for antipsychotics
54. Functional implications of multiple dopamine receptor subtypes: The D1/D3 receptor coexistence
55. Coexpression of dopamine D1 and D3 receptors in islands of Calleja and shell of nucleus accumbens of the rat: Opposite and synergistic functional interactions
56. Opposing roles for dopamine D2 and D3 receptors on neurotensin mRNA expression in nucleus accumbens
57. Combined use of mutant mice and classical pharmacology to characterise receptor functions: The case of dopamine D2 and D3 receptors
58. Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors
59. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice
60. Central administration of dopamine D3 receptor antisense to rat: Effects on locomotion, dopamine release and [3H]spiperone binding
61. D3 receptor knockdown through antisense oligonucleotide administration supports its inhibitory role in locomotion
62. Opposite effects of dopamine D2 and D3 receptors on learning and memory in the rat
63. Behavioural effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other 'D-2-like' agonists
64. Behavioral and biochemical effects of the dopamine D3 receptor-selective ligand, 7-OH-DPAT, in the normal and the reserpine-treated rat
65. Locomotor inhibition by the D3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release
66. Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors
67. Dose-dependent effects of the D3-preferring agonist 7-OH-DPAT on motor behaviors and place conditioning
68. Behavioural effects in the rat of the putative dopamine D3 receptor agonist 7-OH-DPAT: Comparison with quinpirole and apomorphine
69. Dopamine D3 agonists disrupt social behavior in rats
70. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907
71. In vivo occupancy of D2 dopamine receptors by 7-OH-DPAT
72. 7-OH-DPAT injected into the accumbens reduces locomotion and sucrose ingestion: D3 autoreceptor-mediated effects?
73. Effects on locomotor activity after local application of D3 preferring compounds in discrete areas of the rat brain
74. Motor actions of 7-OH-DPAT in normal and reserpine-treated mice suggest involvement of both dopamine D2 and D3 receptors
75. Dopamine D3 receptor agonists produce similar decreases in body temperature and locomotor activity in D3 knock-out and wild-type mice
76. Dopamine D3 receptor mutant and wild-type mice exhibit identical responses to putative D3 receptor-selective agonists and antagonists
77. Dopamine D2 receptor knock-out mice are insensitive to the hypolocomotor and hypothermic effects of dopamine D2/D3 receptor agonists
78. Homozygosity at the dopamine D3 receptor gene is associated with opiate dependence
79. The role of mesoaccumbens-pallidal circuitry in novelty-induced behavioral activation
80. Heterogeneity of behavioural profile between three new putative selective D3 dopamine receptor antagonists using an ethologically based approach
81. Differential effects of dopamine D2 and D3 receptor antagonists in regard to dopamine release, in vivo receptor displacement and behaviour
82. The dopamine D3-receptor: A postsynaptic receptor inhibitory on rat locomotor activity
83. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents
84. (+)-AJ 76 and (+)-UH 232: Central stimulants acting as preferential dopamine autoreceptor antagonists
85. Pharmacological characterization of PD 152255, a novel dimeric benzimidazole dopamine D3 antagonist
86. In vivo occupancy of D2 dopamine receptors by nafadotride
87. Antagonism of cocaine's pharmacological effects by the stimulant dopaminergic antagonists, (+)-AJ76 and (+)-UH232
88. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194
89. NGB 2904 and NGB 2849: Two highly selective dopamine D3 receptor antagonists
90. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626
91. The dopamine D3 receptor and schizophrenia: Pharmacological, anatomical and genetic approaches
92. Decreased binding of dopamine D3 receptors in limbic subregions after neonatal bilateral lesion of rat hippocampus
93. Electrophysiological evidence for A10 dopamine autoreceptor subsensitivity following chronic D-amphetamine treatment
94. Effects of daily cocaine and morphine treatment on somatodendritic and terminal field dopamine release
95. Chronic cocaine treatment impairs the regulation of synaptosomal 3H-DA release by D2 autoreceptors
96. Changes in sensitivity of dopamine autoreceptors in rat striatum after subchronic treatment with methamphetamine
97. Acute amphetamine-induced subsensitivity of A10 dopamine autoreceptors in vitro
98. Effects of repeated administration of the preferential dopamine autoreceptor antagonist, (+)-AJ76, on locomotor activity and brain DA metabolism in the rat
99. Differential regulation, by MK-801, of dopamine receptor gene expression in rat nigrostriatal and mesocorticolimbic systems
100. Phenotypical characterization of neurons expressing the dopamine D3 receptor in the rat brain
101. Lack of autoreceptor-mediated inhibitory control of dopamine release in striatal synaptosomes of D2 receptor-deficient mice
102. Biological consequences of drug administration: Implications for acute and chronic tolerance
103. Current concepts of addiction
104. Morphine tolerance as habituation
105. Homeostatic theory of drug tolerance: A general model of physiological adaptation
106. Learning alcohol tolerance: The contribution of response expectancies
107. Pavlovian influences over food and drug intake
108. The eating paradox: How we tolerate food
109. Regulation of anterior pituitary D2 dopamine receptors by magnesium and sodium ions
110. Dependence of dopamine receptor conversion from agonist high- to low-affinity state on temperature and sodium ions
111. Properties of D2 dopamine receptor autoradiography: High percentage of high-affinity agonist sites and increased nucleotide sensitivity in tissue sections
112. Anatomical and affinity state comparisons between dopamine D1 and D2 receptors in the rat central nervous system
113. Dopamine receptor binding on intact cells. Absence of a high-affinity agonist-receptor binding state
114. The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form
115. Dopamine receptors: Clinical correlates
116. Synaptic concentration of dopamine in the mouse striatum in relationship to the kinetic properties of the dopamine receptors and uptake mechanism
117. Time course of extracellular dopamine and behavioral sensitization to cocaine. I. Dopamine axon terminals
118. Extracellular concentration and in vivo recovery of dopamine in the nucleus accumbens using microdialysis
119. Regulation of transient dopamine concentration gradients in the microenvironment surrounding nerve terminals in the rat striatum
120. Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain
121. Functional and anatomical evidence for different dopamine dynamics in the core and shell of the nucleus accumbens in slices of rat brain
122. Effects of intermittent and continuous cocaine administration on dopamine release and uptake regulation in the striatum: In vitro voltammetric assessment
123. In vivo measurement of dopamine and its metabolites by intracerebral dialysis: Changes after d-amphetamine
124. The role of dopamine in the mouse frontal cortex: A new hypothesis of behavioral sensitization to amphetamine and cocaine
125. The role of dopamine and GABA in the frontal cortex of mice in modulating a motor-stimulant effect of amphetamine and cocaine
126. Interactions between dopamine and excitatory amino acids in behavioral sensitization to psychostimulants
127. D1 receptors modulate glutamate transmission in the ventral tegmental area
128. Dopaminergic modulation of glutamate release in striatum as measured by microdialysis
129. Dopamine regulation of extracellular glutamate in the nucleus accumbens
130. Presynaptic dopamine D2-like receptors inhibit excitatory transmission onto rat ventral tegmental dopaminergic neurones
131. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons
132. Chronic D-amphetamine in nucleus accumbens: Lack of tolerance or reverse tolerance of locomotor activity
133. Amphetamine injection into the ventral mesencephalon sensitizes rats to peripheral amphetamine and cocaine
134. Amphetamine administered to the ventral tegmental area but not to the nucleus accumbens sensitizes rats to systemic morphine: Lack of conditioned effects
135. Evidence of a complete independence of the neurobiological substrates for the induction and expression of behavioral sensitization to amphetamine
136. Sensitization and individual differences to IP amphetamine, cocaine, or caffeine following repeated intracranial amphetamine infusions
137. Amphetamine: Effects on catecholamine systems and behavior
138. Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine
139. Tolerance to ethanol's effects on operant performance in rats: Role of number and pattern of intoxicated practice opportunities
140. Increased locomotor response to novelty and propensity to intravenous amphetamine self-administration in adult offspring of stressed mothers
141. Prenatal stress in rats facilitates amphetamine-induced sensitization and induces long-lasting changes in dopamine receptors in the nucleus accumbens
142. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: A potential animal model of schizophrenia
143. Cocaine-induced behavioral sensitization: Effects of haloperidol and SCH 23390 treatments
144. Interactions between chronic haloperidol treatment and cocaine in rats: An animal model of intermittent cocaine use in neuroleptic treated populations
145. Long-term influence of d-amphetamine on mesolimbic brain-stimulation reward: Comparison to chronic haloperidol and naloxone effects
146. Ethanol reduces tolerance, sensitization, and up-regulation of D2-receptors after subchronic haloperidol
147. Selective antagonism of dopamine D1 and D2 receptors does not block the development of behavioral sensitization to cocaine
148. Clozapine and haloperidol block the induction of behavioral sensitization to amphetamine and associated genomic responses in rats
149. Effects of dopamine antagonism on methamphetamine sensitization: Evaluation by ambulatory activity in mice
150. The role of the frontal cortex in the mouse in behavioral sensitization to amphetamine
151. Early post-treatment with haloperidol retards induction of methamphetamine sensitization in mice
152. Effects of sulpiride and nemonapride, benzamide derivatives having distinct potencies of antagonistic action on dopamine D2 receptors, on sensitization to methamphetamine in mice
153. Effects of selective D-1 and D-2 dopamine antagonists on development of methamphetamine-induced behavioral sensitization
154. The effect of dopamine receptor blockade on the development of sensitization to the locomotor activating effects of amphetamine and morphine
155. The dopamine D3 receptor antagonist nafadotride inhibits development of locomotor sensitization to amphetamine
156. Quantification of dopamine D3 receptor mRNA level associated with the development of amphetamine-induced behavioral sensitization in the rat brain
157. Repeated intravenous cocaine administration: Locomotor activity and dopamine D2/D3 receptors
158. Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities
159. D3 dopamine and kappa opioid receptor alterations in human brain of cocaine-overdose victims
160. Up-regulation of D3 dopamine receptor mRNA in the nucleus accumbens of human cocaine fatalities
161. Repeated cocaine administration causes persistent enhancement of D1 dopamine receptor sensitivity within the rat nucleus accumbens
162. Enhancement of dopamine actions on rat nucleus accumbens neurones in vitro after methamphetamine pre-treatment
163. Chronic cocaine treatment decreases levels of the G protein subunits Gi alpha and Go alpha in discrete regions of rat brain
164. A general role for adaptations in G-proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function
165. Effect of acute and daily cocaine treatment on extracellular dopamine in the nucleus accumbens
166. Long-term amphetamine treatment attenuates or reverses the depression of neuronal activity produced by dopamine agonists in the ventral tegmental area
167. Electrophysiological effects of cocaine in the mesoaccumbens dopamine system: Repeated administration
168. A10 somatodendritic dopamine autoreceptor sensitivity following withdrawal from repeated cocaine treatment
169. Regulation of transmembrane signaling by receptor phosphorylation
170. G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization
171. Regulation of D(1) dopamine receptors with mutations of protein kinase phosphorylation sites: Attenuation of the rate of agonist-induced desensitization
172. Internalization of D1 dopamine receptor in striatal neurons in vivo as evidence of activation by dopamine agonists
173. Resistance of the dopamine D2L receptor to desensitization accompanies the up-regulation of receptors on to the surface of Sf9 cells
174. Regulation of D2 and D3 receptors in transfected cells by agonists and antagonists
175. Human dopamine D3 and D2L receptors couple to inward rectifier potassium channels in mammalian cell lines
176. Ethanol tolerance in the rat is learned
177. Heroin 'overdose' death: Contribution of drug-associated environmental cues
178. Cocaine conditioning and cocaine sensitization: What is the relationship?
179. Characterization of the associative nature of sensitization to amphetamine-induced circling behavior and of the environment dependent placebo-like response
180. Antipsychotic drug doses and neuroleptic/dopamine receptors
181. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs
182. Long-term blockade of the expression of cocaine sensitization by ondansetron, a 5-HT(3) receptor antagonist
183. Cocaine-induced psychosis
184. Clinical features of cocaine-induced paranoia
185. Enhanced response to repeated d-amphetamine challenge: Evidence for behavioral sensitization in humans
186. Progressive behavioral response to repeated d-amphetamine challenge: Further evidence for sensitization in humans
187. Lack of enhanced response to repeated d-amphetamine challenge in first-episode psychosis: Implications for a sensitization model of psychosis in humans
188. Atypical antipsychotic-like effects of the dopamine, D3 receptor agonist(+)-PD 128,907
189. Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia
190. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia
191. Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors
192. Pramipexole as adjunct to haloperidol in schizophrenia. Safety and efficacy
193. Association between schizophrenia and homozygosity at the dopamine D3 receptor gene
194. A meta-analysis and transmission disequilibrium study of association between the dopamine D3 receptor gene and schizophrenia
195. Trend for an association between schizophrenia and D3S1310, a marker in proximity to the dopamine D3 receptor gene
196. Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia
197. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study
198. Neural systems for behavioral activation and reward
199. A common mechanism mediates long-term changes in synaptic transmission after chronic cocaine and morphine
200. Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area